The insulin effect on glucose uptake is not sufficiently explained by a simple glucose-carrier translocation model. Recent studies rather suggest a two-step model of carrier translocation and carrier activation. We used several pharmacological tools to characterize the proposed model further. We found that inositol phosphate (IP)-oligosaccharides isolated from the drug Actovegin, as well as the alkaloid vinblastine, show a partial insulin-like effect on glucose-transport activity of fat-cells (3-O-methylglucose uptake, expressed as %0 of equilibrium value per 4 s: basal 5.8%, insulin 59 %, IP-oligosaccharides 30 %, vinblastine 29 %) without inducing carrier translocation. On the other hand, two newly developed anti-diabetic compounds (a-activated carbonic acids, BM 130795 and BM 13907) induced carrier translocation to the same extent as insulin and phorbol esters [cytochalasin-B-binding sites in plasma membranes: basal 5 pmol/mg of protein, insulin 13 pmol/mg of protein, TPA (12-O-tetradecanoylphorbol 13-acetate) 11.8 pmol/mg of protein, BM 130795 10.8 pmol/mg of protein], but produce also only 40-50 % of the insulin effect on glucosetransport activity (basal 5.8%, insulin 59 %, TPA 23 %, BM 130795 35 %). Almost the full insulin effect was mimicked by a combination of phorbol esters and IP-oligosaccharides (basal 700, insulin 5000, IP-oligosaccharides 300, TPA 23 %, IP-oligosaccharides + TPA 45 %). None of these substances stimulated insulin-receptor kianse in vitro or in vivo, suggesting a post-kinase site of action. The data confirm the following aspects of the proposed model: (1) carrier translocation and carrier activation are two independently regulated processes; (2) the full insulin effect is mimicked only by a simultaneous stimulation of carrier translocation and intrinsic carrier activity, suggesting that insulin acts through a synergism of both mechanisms; (3) IP-oligosaccharides might be involved in the transmission of a stimulatory signal on carrier activity.
INTRODUCTION
Insulin stimulates in vitro the glucose-transport activity of isolated fat-cells. Cushman and co-workers (Wardzala et al., 1981) , using different experimental approaches, have shown that the activation of the glucose-transport activity is paralleled by a translocation of glucose carriers from intracellular storage sites to the plasma membrane, and have proposed that carrier translocation is the molecular basis of glucose-transport activation by insulin . This mechanism was widely accepted, but more recently a number of observations in several experimental systems were difficult to reconcile with a pure translocation model. It was shown by several experimental systems were difficult to reconcile with a pure translocation model. It was shown by several investigators (Joost et al., 1986; Kahn & Cushman, 1987; Matthaei et al., 1987; Karnieli et al., 1987; Muhlbacher et al., 1988) that under certain conditions glucose-transport activity and carrier numbers in the plasma membrane are not sufficiently correlated. Furthermore, we have shown (Muhlbacher et al., 1988 ) that phorbol esters mimic quantitatively the insulin effect on carrier translocation without mimicking the full insulin effect on transport activity. We concluded that insulininduced glucose-carrier translocation is followed or paralleled by a second step, apparently an activation of carriers which is necessary to reach the full extent of the insulin response. Subsequently we showed that an activation of carriers without carrier translocation is induced by AlCl3, presumably through activation of a G-protein, and by phospholipase C (Obermaier-Kusser et al., 1988) . On the basis of these data, we proposed as a working hypothesis a model of glucose-transport regulation in fat-cells with the following characteristics: (1) carrier translocation and regulation of carrier activity are two independent mechanisms; (2) the insulin effect requires the additive action of both mechanisms; (3) carrier translocation is a protein kinase C-dependent step; carrier activation involves G-proteins and phospholipases.
In the present paper we used a number of pharmacological tools to evaluate this concept. We tested among other substances potential products of cleavage by phospholipases. The results are consistent with the proposed model. Furthermore, the data show that glucose-carrier activity can be selectively stimulated by an inositol phosphate (IP)-oligosaccharide fraction which resembles a possible cleavage product of a phospholipase C, supporting the idea that a stimulatory signal on intrinsic carrier activity might involve cleavage of membrane glycolipids by a phospholipase.
MATERIALS AND METHODS

Materials
Pig insulin was purchased from Novo Industrie (Bagsvaerd, Denmark), [3H]cytochalasin B and ['4C]urea were from New England Nuclear (Dreieich, Germany), and TPA (12-O-tetradecanoylphorbol 13-acetate), cytochalasins and the 5'-nucleotidase enzyme kit were from Sigma (Munich, Germany). The a-activated carbonic acids BM 130795 [(± )-7-(4-chlorophenyl)-2-(4-methylphenylsulphonyl)heptanoic acid, sodium salt] and BM 13907 [(± )-5-(4-chlorophenyl)-2-(4-methylphenylsulphonyl)pent-4-ynoic acid], acting as anti-diabetic drugs, and the inactive analogue BM 13705 [5-(2-phenylethenyl)isoxazolidin-3-carboxylic acid] were from Boehringer (Mannheim, Germany). Vinblastine was from Sigma, and the commercially available drug Actovegin was from Hormon Chemie (Munich, Germany). All other reagents were of the best grade commercially available. Cell isolation and determination of 3-0-methylglucose transport Rat adipocytes were prepared as described by Haring et al. (1981) from male Sprague-Dawley rats fed ad libitum (180-220 g body wt.). Incubation was carried out at 37°C in the absence (basal) or the presence of insulin, or with other substances mentioned in the Figure legends. The phorbol ester TPA was diluted in pure ethanol, dried with N2, taken up in incubation buffer and sonicated. The BM substances were dissolved in 1 M-NaOH (6 mg of BM in 100,1u of 1 M-NaOH), vortex-mixed and adjusted to the final concentrations in incubation buffer. Vinblastine was dissolved in 0.900 NaCl, and IPoligosaccharides were dissolved in distilled water. Glucose-transport activity was measured as described by Haring et al. (1981) . Subcellular fractionation of adipose cells and cytochalasin-B-binding (CBB) assay Plasma-and microsomal-membrane fractions were prepared as described previously (McKeel & Jarrett, 1970; Karnieli et al., 1981; Muhlbacher et al., 1988) . The concentration of D-glucose transporters in the membrane fractions was assessed by using a specific D-glucoseinhibitable CBB assay (Wardzala et al., 1978; Karnieli et al., 1981) . The CBB assay was carried out as outlined by Muhlbacher et al. (1988) , and analysed with a computer program published by McPherson (1985) . Insulin-receptor kinase solubilization and autophosphorylation in vitro; determination of kinase activity in vivo Partially purified insulin receptor was prepared and phosphorylated in vitro as described by Haring et al. (1986) . The activation of the receptor kinase in vivo was assessed as described by Klein et al. (1986) . Briefly, fatcells were stimulated with insulin, IP-oligosaccharides or BM substances. Insulin receptor was then purified as described by HWring et al. (1986) , but in the presence of vanadate (1 mM). Kinase activity was then measured with poly(Glu-Tyr) as substrate as described by HWring et al. (1986) . Isolation of active IP-oligosaccharide fractions from the drug Actovegin Actovegin, which is derived from calf blood, was precipitated with ethanol and applied to a TSK-HW 40 column. The eluted 1 ml fractions were assayed for their ability to stimulate lipogenesis from D-[3H]glucose as well as for their anti-lipolytic effect against isoprenaline in adipocytes (F. Machicao & V. Christoffel, unpublished work) . The fraction with the highest lipogenic activity, designated P1, was used in our studies. This fraction contained predominantly carbohydrates (F. Machicao & V. Christoffel, unpublished work) . To characterize the carbohydrate composition of this fraction, hydrolysis, reduction and derivative formation were performed as follows: (1) hydrolysis to generate monosaccharides with 2 M-HCl at 100°C for 2-4 h; (2) reduction with 50 mMNaOH/0.5 M-NaBH4; (3) ion-exchange chromatography with Dowex AG 50W X8; (4) acetylation with acetic anhydride in pyridine; (5) free saccharides were then isolated and identified by g.l.c. (Supelco column; 912 mm x 2 mm; 180-220°C, gradient of 2°C/min).
RESULTS
Description of substances acting like insulin
In order to find pharmacological tools to be used as selective stimulators of glucose-carrier translocation or glucose-carrier activation, we tested agents which were potential candidates as substances acting like insulin.
(1) The phosphatidylinositol cycle is an important signal-transmitting system at the plasma membrane (Berridge, 1984) . Activation of the key enzyme of this cycle, the phospholipase C, leads to generation of signaltransmitting compounds. As potential products of cleavage by phospholipase C, we tested diacylglycerol, inositol tris-and mono-phosphate, as well as myo-inositol.
(2) It was proposed that phsophatidylinositol-containing glycolipids are the source of second-messenger substances of insulin action (Saltiel & Cuatrecasas, 1986; Fox et al., 1987; Mato et al., 1987; Alemany et al., 1987;  for review, see Low & Saltiel, 1988) . The compounds tested so far were isolated from liver, and did not stimulate glucose transport . We tested an IP-oligosaccharide fraction isolated from the drug Actovegin as described in the Materials and methods section (F. Machicao & V. Christoffel, unpublished work). The contents of neutral sugars and inositol measured as alditol acetates by g.l.c. are described in the legend of Fig. 1 . For further chemical characterization of this fraction, particularly to compare its characteristics with those reported by Saltiel & Cuatrecasas (1986) and Low & Saltiel (1988) , the following inactivation treatments were applied, and the remaining activity was determined in the lipogenesis assay. The activity after each treatment is expressed as a percentage (numbers in parentheses) of the control activity: no treatment (control, 100 0 lipogenesis activity), treatment with 2 M-HCl (54 o), 1% NH3 (70 %), IO o NH3 (58 /), 0.2 M-NaNO2, pH 3.7 (100 %o), methanol/HCl (24 %O), NaBH4 (50 %o), HNO3 (42 %O), acetylated (38 %o). The lipogenic activity of this fraction could be inhibited by inositol monophosphate (0.3-2.5 mM) as described also by Saltiel & Sorbara-Cazan (1987) for their inositol phosphateglycan. 1251-insulin binding to fat-cells was not altered by the active fraction. The results of the chemical analysis and the inactivation procedure suggest that the active compound contained in this IP-oligosaccharide fraction has many homologies with, but also some composition differences from, those IP-glycans described as putative second messengers (Saltiel & Cuatrecasas, 1986; Fox et al., 1987; Mato et al., 1987; Alemany et al., 1987; Low & Saltiel, 1988 (4) Furthermore, the effect of the alkaloid vinblastine on glucose-transport activity was investigated: vinblastine binds to the microtubular system and alters its function (Olmsted & Borisy, 1973) . The effect of these substances on glucose-transport activity and CBB is described in the following paragraphs. Stimulation of 3-O-methylglucose transport There is a stimulatory effect of diacylglycerol (0.25 mM), but no significant effects of inositol I-phosphate, inositol 1,4,5-trisphosphate and myo-inositol (all 0.25 mM; stimulation factors over basal: diacylglycerol 3.3+0.6, n = 5; inositol trisphosphate 1.7+0.7, n = 5; inositol monophosphate 1.7 + 0.1, n = 2; myo-inositol 2.4 + 1.1, n = 4). In contrast, the IP-oligosaccharide fraction, the BM substances and the alkaloid vinblastine showed significant effects. Fig. 1(a) shows the dose-response effect of the IP-oligosaccharides on glucose transport. Insulin was used as a reference; it stimulates glucose transport in a dose-dependent way up to 10-fold. The IP-oligosaccharide fraction stimulates in a dose-dependent way up to approx. 5-fold. The effect of the oligosaccharide fraction occurs as rapidly as the insulin effect (Fig. lb) . The time course of the effect of the IP-oligosaccharide fraction and, for comparison again, the effect of insulin, which was measured in parallel, are shown in Fig. 1(b) . Both agents start to act within 1 min and reach maximal values after 5 min. Acetylation of the IP-oligosaccharide fraction decreased the effect by approx. 50 %. Fig. 2 shows the dose-response effect of the substances BM 13907 and BM 130795, and BM 13705, which was used as inactive analogue. BM 13907 and BM 130795 stimulate in a dose-dependent way the glucose-transport activity of fat-cells. BM 130795 mimics the insulin effect by 40-60 %, i.e. it causes a 5-6-fold stimulation. Again, a similar time course to that with insulin is found (results not shown). Fig. 3(a) shows the effect of vinblastine on glucose transport; up to 400 of the insulin effect is reached, and a similar time course to that with insulin was found (Fig. 3b) .
Effect on glucose-carrier numbers in the plasma membranes: determination of CBB sites in subcellular membrane fractions We studied the effect of the active substances on the concentration of glucose carriers in plasma membranes and low-density membranes. Fig. 4 shows the CBB data for plasma-membrane fractions of isolated fat-cells (Fig.  4b) and, in summary also the effect of these substances on glucose-transport activity (Fig. 4a) . As a further control substance besides insulin, the phorbol ester TPA was also used. None of these compounds altered the previously described (Miihlbacher et al., 1988) distribution of marker enzymes in the membrane preparation.
The BM substances and TPA were the only compounds acting like insulin which led to glucose-carrier translocation. Insulin increases the glucose-carrier number in the plasma-membrane fraction from 5 to 13 pmol. BM 13907, which is less active in glucose-transport activity stimulation, also has a smaller effect on carrier translocation, whereas TPA and BM 130795 have the same effect as insulin. None of the other substances which stimulated glucose transport in fat-cells caused an increase of CBB sites in the plasma-membrane fraction. The increase of CBB sites leads, in the case of insulin, to an approx. 10-fold stimulation of the glucose-transport activity of the fat-cells, whereas TPA and BM substances cause only an approx. 3-6-fold stimulation of the glucose- Effect on tyrosine kinase activity of the insulin receptor It appears that the substances tested above consist of two sub-groups. In order to localize further the site of action of each group, we tested whether the insulin-like effects of these substances occur through stimulation of the insulin-receptor tyrosine kinase. Combination of substances acting on glucose-carrier translocation with substances acting on glucosecarrier activity
The observation that neither substances of the translocation-stimulating group nor those of the carrieractivating group are able to mimic the full insulin effect suggests the possibility that the insulin effect occurs through an additive action on carrier translocation
Vol. 261 and carrier activation. Therefore we tested whether substances acting on translocation and those acting on carrier activity have additive effects on the glucosetransport activity in fat-cells. The combination of TPA and the IP-oligosaccharide fraction showed an additive effect, whereas the combination of BM substances with IP-oligosaccharides was inhibitory. The reason for this inhibitory effect is not known; however, a direct drug interaction seems a good possibility. The additive effect of the combination of TPA and IP-oligosaccharides is shown in Fig. 5 Kahn & Cushman (1987) in fat-cells of streptozotocin-diabetic rats led to the same conclusion. Furthermore, a direct insulin effect on glucose-transport affinities was shown (Greco-Perotto et al., 1987) . Finally, our own results with phorbol esters and insulin were incompatible with an unmodified translocation model (Miihlbacher et al., 1988) . Our study had suggested that insulin itself can rapidly up-regulate the intrinsic carrier activity. This conclusion confirms some of the ideas from earlier work by Carter-Su & Czech (1980) , followed by phosphorylation of substrates in the cell Haring et al., 1987; Bernier et al., 1987; Perrotti et al., 1987; Machicao et al., 1987) . The further signaltransmitting steps linking the insulin-receptor kinase to the glucose-transport system are not understood in detail. The observation that none of the substances tested here activates the insulin-receptor kinase suggests that these substances act at the post-kinase level. As both groups of substances regulate selectively either carrier activity or carrier translocation, it may be concluded that two distinct and independent signal transmitting chains exist at the post-kinase level. Signal transfer on carrier activity: possible role of IP-oligosaccharides
There is now some evidence that the signal-transmitting chain which regulates carrier activity might involve G-proteins (Obermaier-Kusser et al., 1988; O'Brien et al., 1987; Zick et al., 1986 ) and activation of phospholipases (Obermaier-Kusser et al., 1988; Fox et al., 1987; Mato et al., 1987; Koepfer-Hobelsberger & Wieland, 1984) . Among potential signal-transmitting compounds generated by the activation of phospholipases are the cleavage products of phosphatidylinositol. Consistent with this concept and a recent publication (Standaert et al., 1988) , diacylglycerol stimulated glucose transport to the same extent as TPA, and we assume through the same mechanism as TPA. However, in contrast with this concept, the inositol phosphates had no clear stimulating effect. Therefore it is unlikely that phosphatidylinositol is a relevant phospholipase C substrate involved in regulation of carrier activity. On the other hand, the IP-oligosaccharide mixture is a strong stimulator, suggesting the possibility that a glycolipid is the relevant substrate of a phospholipase C involved in insulin action. A role of membrane glycolipids in insulin action was proposed by Saltiel and colleagues (Saltiel et al., 1986; Fox et al., 1987; Low & Saltiel, 1988) and others Alemany et al., 1987) . Alemany et al. (1987) have published that these polar substances can activate lipogenesis in intact cells, and it appears that an uptake mechanism exists for these compounds (Saltiel & Sorbara-Cazan, 1987) . However, the putative secondmessenger IP-oligosaccharides isolated from liver do not stimulate glucose transport . This is in contrast with our findings with the IP-oligosaccharides from Actovegin, and it suggests that different insulin effects involve different IP-glycans. A further separation of the compounds in our IP-oligosaccharide mixture will hopefully allow identification of this particular IPoligosaccharide, and will then also allow identification of an analogous compound in the intact cell and a study of whether its cleavage indeed correlates with an insulininduced modulation of the intrinsic carrier activity.
